Strategic partnerships Leverage CLB101 as a next-generation probiotic with targeted gut butyrate production to form collaborations with healthcare practitioner brands and nutrition companies looking to expand gut health portfolios.

Clinical and clinical-adjacent opportunities Position CLB101 for integration into clinical nutrition programs and GI-focused treatment pathways, targeting clinics, hospitals, and research centers exploring innovative microbiome-based interventions for IBD and food allergies.

Healthcare practitioner channels Capitalize on ongoing launches and practitioner-focused distribution by engaging dietary supplement distributors and medical nutrition retailers to reach clinicians and specialized patient populations.

Geographic and market momentum Highlight Chicago-based innovation accolades and recent awards to attract regional distributors and biopharma interest, while expanding into national networks aligned with biotech startups and gut health markets.

Digital engagement leverage Utilize the CLB101 proof points and education campaigns to drive targeted demand via digital marketing partnerships, influencer clinicians, and patient advocacy groups to accelerate adoption and trials.